September 2024

Biohaven announces positive results in their study of Troriluzole for Spinocerebellar ataxia (SCA)

Leave a Comment / Cerebellar ataxia, Research /

On September 23rd, 2024, the pharmaceutical company Biohaven announced positive topline results from their study of the drug Troriluzole to treat SCAs 1,2,3,6,7,8 and 10.    Those with SCA who were treated with Troriluzole showed a 50 – 70% slowing of disease progression, compared to those with SCA who were untreated over a 3-year study […]

Biohaven announces positive results in their study of Troriluzole for Spinocerebellar ataxia (SCA) Read More »

Satisfaction is significantly higher in those attending UK specialist ataxia centres compared with those who do not, new paper shows

Leave a Comment / ARSACS, Cerebellar ataxia, Friedreich's ataxia, Research, SPG-7 /

Ataxia UK has worked closely with the London Ataxia Centre researchers and other experts on a research study assessing the impact of specialist ataxia centres in Europe. This was part of the Value of Treatment (VoT) project supported by the European Brain Council, a non-profit organisation which promotes brain research to improve the lives of

Satisfaction is significantly higher in those attending UK specialist ataxia centres compared with those who do not, new paper shows Read More »

Scroll to Top